FAS and medulloblastoma: During medulloblastoma therapy combining the topoisomerase I inhibitor camptothecin (CPT) and the agonistic anti-Fas antibody (CH-11), it was shown that these agents synergize with Fas activation to induce cell death through mechanisms involving ROS and oxidative stress pathways [45].